Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.86 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.86 |
| ▸ | PGRMC1 | O00264 | 1/20 | 0.86 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.86 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.86 |
| ▸ | CDK4 | P11802 | 1/20 | 0.86 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.86 |
| ▸ | CCKBR | P32239 | 1/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.86 |
| ▸ | HTR2B | P41595 | 1/20 | 0.86 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.86 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.86 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.86 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.86 |
| ▸ | PCYT1A | P49585 | 1/20 | 0.86 |
| ▸ | GSK3A | P49840 | 1/20 | 0.86 |
| ▸ | GSK3B | P49841 | 1/20 | 0.86 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.86 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.86 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234125 | 1.00 | BRAF (0.86) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL15732609 | 1.00 | BRAF (0.86) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL8233923 | 0.93 | BRAF (0.75) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL29368575 | 0.93 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL8512458 | 0.93 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL8231398 | 0.93 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL8228295 | 0.93 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| Encorafenib SCHEMBL31210316 | 0.93 | BRAF (1.00) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL15732615 | 0.92 | BRAF (0.86) | BRAFMAPK14PGRMC1RIPK2NR1I2 | |
| SCHEMBL15732391 | 0.92 | BRAF (0.87) | BRAFMAPK14PGRMC1RIPK2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| EP-3693741-B1 | MEDICAL USES INVOLVING C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA FARBER CANCER INST INC (US) | 2022-01-05 | — | — | EP | claimed |
| EP-3333575-B1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA FARBER CANCER INST INC (US) | 2020-02-26 | — | — | EP | claimed |
| US-10561654-B2 | Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | ARRAY BIOPHARMA INC. (US) | 2020-02-18 | — | — | US | claimed |
| US-10258622-B2 | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate | ARRAY BIOPHARMA INC. (US) | 2019-04-16 | — | — | US | claimed |
| US-20190054086-A1 | PHARMACEUTICAL FORMULATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2019-02-21 | — | — | US | claimed |
| EP-2782557-B1 | PHARMACEUTICAL FORMULATIONS | ARRAY BIOPHARMA INC (US) | 2018-09-12 | — | — | EP | claimed |
| US-9763941-B2 | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | ARRAY BIOPHARMA, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20170202837-A1 | PHARMACEUTICAL FORMULATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | 2017-07-20 | — | — | US | claimed |
| US-9387208-B2 | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | NOVARTIS AG (CH) | 2016-07-12 | — | — | US | claimed |
| EP-2831589-A1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2015-02-04 | — | — | EP | claimed |
| WO-2013148100-A1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-10-03 | — | — | WO | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4321165-A2 | METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION, DIAGNOSTIC AGENT, THERAPEUTIC AGENT, AND SCREENING METHOD FOR SAID AGENTS | National University Corporation Tokyo Medical and Dental University (JP) | 2024-02-14 | — | — | EP | disclosed |
| US-20230044943-A1 | Pharmaceutical Combinations | ARRAY BIOPHARMA INC (US) | 2023-02-09 | — | — | US | disclosed |
| CN-103945831-A | pharmaceutical preparation | NOVARTIS AG | 2014-07-23 | — | — | CN | disclosed |
| WO-2013148100-A1 | C-RAF MUTANTS THAT CONFER RESISTANCE TO RAF INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013078264-A1 | PHARMACEUTICAL FORMULATIONS | NOVARTIS AG (CH) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078264-A1 | PHARMACEUTICAL FORMULATIONS | NOVARTIS AG (CH) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258622-B2 | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate | APC, CCNY, SKP1 | BRAF 199/4885MAPK14 3627/4885PGRMC1 1157/4885 |
| US-20170202837-A1 | PHARMACEUTICAL FORMULATIONS | VHL, SP1, PHF8 | BRAF 722/4885MAPK14 3492/4885PGRMC1 1019/4885 |
| US-20230044943-A1 | Pharmaceutical Combinations | BRAF, NRAS, KRAS | BRAF 1/4885MAPK14 40/4885PGRMC1 794/4885 |
| US-20190054086-A1 | PHARMACEUTICAL FORMULATIONS | PKD1, TP53, PKD2 | BRAF 194/4885MAPK14 3635/4885PGRMC1 1323/4885 |
| US-10561654-B2 | Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | PKD1, SP1, PKD2 | BRAF 211/4885MAPK14 3308/4885PGRMC1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.